Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease.
Name:
PIIS1525730416302273.pdf
Size:
418.6Kb
Format:
PDF
Description:
Full text, Open Access Article
Authors
Socinski, MKaye, F
Spigel, D
Kudrik, F
Ponce, S
Ellis, P
Majem, M
Lorigan, Paul C
Gandhi, L
Gutierrez, M
Nepert, D
Corral, J
Ares, L
Affiliation
Division of Hematology/Oncology, Univeristy of Pittsburgh Cancer Institute, Pittsburgh, PAIssue Date
2017-01
Metadata
Show full item recordAbstract
This trial assessed the safety and efficacy of LM in combination with carboplatin/etoposide therapy compared to carboplatin/etoposide treatment alone in patients with previously untreated extensive-disease small-cell lung cancer (ED-SCLC).Citation
Phase 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. 2017, 18(1):68-76.e2 Clin Lung CancerJournal
Clinical Lung CancerDOI
10.1016/j.cllc.2016.09.002PubMed ID
28341109Type
ArticleLanguage
enISSN
1938-0690ae974a485f413a2113503eed53cd6c53
10.1016/j.cllc.2016.09.002
Scopus Count
Collections
Related articles
- Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
- Authors: Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ
- Issue date: 2014 Mar-Apr
- Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
- Authors: Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigators
- Issue date: 2021 Jan
- Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
- Authors: Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U
- Issue date: 2009 Feb
- A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.
- Authors: Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M
- Issue date: 2017 Nov
- A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.
- Authors: Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, Katakami N, Shibuya M, Saijo N, Fukuoka M
- Issue date: 2014 Mar